Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss

Published:October 16, 2020DOI:https://doi.org/10.1016/j.gie.2020.10.016

      Background and Aims

      Endoscopic sleeve gastroplasty (ESG) has been shown to be effective for inducing weight loss. The efficacy of liraglutide, a glucagon-like peptide-1 agonist, to augment weight loss after ESG is unknown. This study aims to evaluate the efficacy of ESG and liraglutide (ESG-L) compared with ESG alone.


      This was a retrospective study of prospectively collected data from patients undergoing ESG at 3 outpatient clinics in Brazil between November 2017 and July 2018. Liraglutide was offered to all patients 5 months after ESG. Patients who opted to take liraglutide (ESG-L) were matched 1:1 to patients who declined it (ESG). The primary outcome was percent total body weight loss (%TBWL), and percent excess weight loss (%EWL) 7 months after initiation of liraglutide (12 months after ESG). The secondary outcome was change in percent body fat 12 months after ESG. ESG technique and postprocedure follow-up were identical at all 3 sites.


      Propensity score matching yielded 26 matched pairs. Adjusted comparisons between the 2 groups showed that patients who opted to take liraglutide had a superior mean %TBWL 7 months after initiation of liraglutide (ESG-L) compared with those who declined it (ESG) (24.72% ± 2.12% vs 20.51% ± 1.68%, respectively; P < .001). ESG-L had a statistically greater reduction in percent body fat compared with ESG (7.85% ± 1.26% vs 10.54% ± 1.88%, respectively; P < .001) at 12 months.


      Addition of liraglutide at 5 months results in superior weight loss and improved efficacy as demonstrated by decreased body fat 12 months after ESG. Further studies are imperative to determine optimal dose, timing, and duration of liraglutide.


      BMI (body mass index), EBT (endoscopic bariatric therapy), ESG (endoscopic sleeve gastroplasty), ESG-L (endoscopic sleeve gastroplasty and liraglutide), HbA1c (hemoglobin A1c), HTN (hypertension), IGB (intragastric balloon), %EWL (percent excess weight loss), %TBWL (percent total body weight loss)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Afshin A.
        • Forouzanfar M.H.
        • Reitsma M.B.
        • et al.
        Health effects of overweight and obesity in 195 countries over 25 years.
        N Engl J Med. 2017; 377: 13-27
        • Hales C.M.
        • Carroll M.D.
        • Fryar C.D.
        • et al.
        Prevalence of obesity among adults and youth: United States, 2015-2016.
        NCHS data brief. 2017; 288: 1-8
        • Kim D.D.
        • Basu A.
        Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis.
        Value Health. 2016; 19: 602-613
        • Kushner R.F.
        • Kahan S.
        Introduction: the state of obesity in 2017.
        Med Clin North Am. 2018; 102: 1-11
        • Wing R.R.
        • Bolin P.
        • Brancati F.L.
        • et al.
        Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
        N Engl J Med. 2013; 369: 145-154
        • Wing R.R.
        • Koeske R.
        • Epstein L.H.
        • et al.
        Long-term effects of modest weight loss in type II diabetic patients.
        Arch Intern Med. 1987; 147: 1749-1753
        • Jensen M.D.
        • Ryan D.H.
        • Apovian C.M.
        • et al.
        2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
        Circulation. 2014; 129: S102-S138
        • Vigneri P.
        • Frasca F.
        • Sciacca L.
        • et al.
        Obesity and cancer.
        Nutr Metab Cardiovasc Dis. 2006; 16: 1-7
        • Adams K.F.
        • Schatzkin A.
        • Harris T.B.
        • et al.
        Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.
        N Engl J Med. 2006; 355: 763-778
        • Wing R.R.
        • Lang W.
        • Wadden T.A.
        • et al.
        Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
        Diabetes Care. 2011; 34: 1481-1486
        • Magkos F.
        • Fraterrigo G.
        • Yoshino J.
        • et al.
        Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity.
        Cell Metab. 2016; 23: 591-601
        • Gregg E.W.
        • Jakicic J.M.
        • Blackburn G.
        • et al.
        Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.
        Lancet Diabetes Endocrinol. 2016; 4: 913-921
        • Vilar-Gomez E.
        • Martinez-Perez Y.
        • Calzadilla-Bertot L.
        • et al.
        Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.
        Gastroenterology. 2015; 149 (quiz e14-5): 367-378
        • Hedjoudje A.
        • Dayyeh B.A.
        • Cheskin L.J.
        • et al.
        Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2020; 18: 1043-1053.e4
        • Alqahtani A.
        • Al-Darwish A.
        • Mahmoud A.E.
        • et al.
        Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients.
        Gastrointest Endosc. 2019; 89: 1132-1138
        • Davies M.J.
        • Bergenstal R.
        • Bode B.
        • et al.
        Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.
        JAMA. 2015; 314: 687-699
        • Hajifathalian K.
        • Mehta A.
        • Shah S.L.
        • et al.
        Efficacy of pharmacotherapy in the treatment of weight regain and inadequate weight loss following endoscopic sleeve gastroplasty.
        Gastroenterology. 2019; 156: S1168-S1169
        • Mosli M.M.
        • Elyas M.
        Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?.
        Saudi J Gastroenterol. 2017; 23: 117-122
        • Demura S.
        • Sato S.
        • Kitabayashi T.
        Percentage of total body fat as estimated by three automatic bioelectrical impedance analyzers.
        J Physiol Anthropol Appl Hum Sci. 2004; 23: 93-99
        • Ling C.H.
        • de Craen A.J.
        • Slagboom P.E.
        • et al.
        Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population.
        Clin Nutr. 2011; 30: 610-615
        • Cotton P.B.
        • Eisen G.M.
        • Aabakken L.
        • et al.
        A lexicon for endoscopic adverse events: report of an ASGE workshop.
        Gastrointest Endosc. 2010; 71: 446-454
        • Barrichello S.
        • Hourneaux de Moura D.T.
        • Hourneaux de Moura E.G.
        • et al.
        Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study.
        Gastrointest Endosc. 2019; 90: 770-780
        • Garber A.
        • Henry R.
        • Ratner R.
        • et al.
        Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
        Lancet. 2009; 373: 473-481
        • Pi-Sunyer X.
        • Astrup A.
        • Fujioka K.
        • et al.
        A randomized, controlled trial of 3.0 mg of liraglutide in weight management.
        N Engl J Med. 2015; 373: 11-22
      1. Saxenda (liraglutide), US Food and Drug Administration approval for weight management. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/206321Orig1s004.pdf.

        • Apovian C.M.
        • Aronne L.J.
        • Bessesen D.H.
        • et al.
        Pharmacological management of obesity: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362
      2. Saxenda liraglutide injection [package insert]. Novo Nordisk, Plainsboro, NJ2015
        • D'Agostino Jr., R.B.
        Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
        Stat Med. 1998; 17: 2265-2281
        • Cheskin L.J.
        • Hill C.
        • Adam A.
        • et al.
        Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study.
        Gastrointest Endosc. 2020; 91: 342-349
        • Abu Dayyeh B.K.
        • Acosta A.
        • Camilleri M.
        • et al.
        Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals.
        Clin Gastroenterol Hepatol. 2017; 15: 37-43
        • Fayad L.
        • Adam A.
        • Schweitzer M.
        • et al.
        Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study.
        Gastrointest Endosc. 2019; 89: 782-788
        • Rega-Kaun G.
        • Kaun C.
        • Jaegersberger G.
        • et al.
        Roux-en-Y-bariatric surgery reduces markers of metabolic syndrome in morbidly obese patients.
        Obes Surg. 2019;
        • Sjostrom L.
        Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery.
        J Intern Med. 2013; 273: 219-234
        • Rega-Kaun G.
        • Kaun C.
        • Jaegersberger G.
        • et al.
        Roux-en-Y-bariatric surgery reduces markers of metabolic syndrome in morbidly obese patients.
        Obes Surg. 2020; 30: 391-400
        • Nauck M.A.
        • Niedereichholz U.
        • Ettler R.
        • et al.
        Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
        Am J Physiol. 1997; 273: E981-E988
        • Flint A.
        • Raben A.
        • Astrup A.
        • et al.
        Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
        J Clin Invest. 1998; 101: 515-520
        • Blonde L.
        • Russell-Jones D.
        The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
        Diabetes Obes Metabol. 2009; 11: 26-34
        • Wadden T.A.
        • Hollander P.
        • Klein S.
        • et al.
        Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
        Int J Obes. 2013; 37: 1443-1451
        • Astrup A.
        • Rossner S.
        • Van Gaal L.
        • et al.
        Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
        Lancet. 2009; 374: 1606-1616
        • Rye P.
        • Modi R.
        • Cawsey S.
        • et al.
        Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery.
        Obes Surg. 2018; 28: 3553-3558
        • Pajecki D.
        • Halpern A.
        • Cercato C.
        • et al.
        Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.
        Rev Col Brasil Cirurg. 2013; 40: 191-195
        • Nor Hanipah Z.
        • Nasr E.C.
        • Bucak E.
        • et al.
        Efficacy of adjuvant weight loss medication after bariatric surgery.
        Surg Obes Relat Dis. 2018; 14: 93-98